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Abstract Human protbymosin a mutants were generated with 
the aid of random mutagenesis and screened for their ability to 
inhibit yeast Saccharomyces cerevisiue cell growth. Conversion 
of Lys-87 to Glu resulted in an inactivated prothymosin a 
mutant, which lost the ability of the wild-type protein to block 
yeast cell growth. We propose that prothymosin a may possess a 
bipartite rather than monopartite nuclear localization signal, 
which includes Lys-87, and that the above mutation destroys one 
part of the nuclear localization signal, thus preventing efficient 
nuclear uptake of prothymosin a. 
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1. Introduction 
Prothymosin a (ProTa) is a highly acidic small nuclear 
protein [l-6]. ProTa appears to be an abundant and essential 
protein in mammalian cells [7,8]. Although the exact function 
of this protein is unknown, available evidence strongly sug- 
gests that ProTa is related to cell proliferation [2,7,9,10]. In 
an attempt to elucidate the function of ProTa, we began the 
generation and characterisation of random ProTa mutants 
with altered properties of the protein. The selection procedure 
for the mutants was based on the recently observed phenom- 
enon that the wild-type human ProTa, being overproduced in 
yeast Saccharomyces cerevisiae, efficiently inhibited cell 
growth [l 11. Here we report that the point mutation Lyss7Glu 
in human ProTa eliminates inhibitory potential of human 
ProTa towards yeast cell growth. Possible implications of 
this fact are discussed. 
2. Materials and methods 
Escherichia coli JM109 and S. cerevisiae 2805 [MATa, pepl::His3, 
prb I-6, canl, Ga12, his36, ura3-521 strains were used throughout this 
work. Standard procedures for DNA cloning were employed. 
Conditions for PCR-based random mutagenesis of the human 
ProTcc cDNA were essentially as described [12]. Briefly, 5 ng of 
pHTl5 [13] were taken for PCR amplification of ProTcl cDNA with 
0.2 pg of each direct and reverse pUC19 primers in the reaction buffer 
containing 20 mM Tris-HCl (pH 8.4), 50 mM KCI, 2.5 mM MgClz, 
0.5 mM MnC12, 0.1 mg/ml BSA and 5U of Tuq polymerase in the 
presence of 250 FM each of dGTP, TTP, dCTP and 50 pM dATP. 25 
cycles of PCR were performed with the following temperature profile: 
94”C, 1 min; 48”C, 1 min; 72”C, 0.5 min. The PCR products were 
fractionated in a 1.5% agarose gel, eluted and digested with BamHI 
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and EcoRI. The resultant 350 bp long DNA fragments were ligated 
with the BamHI-EcoRI digested pYeDP1/8-2 yeast shuttle vector [14]. 
Yeast cells were transformed with the plasmids by the DMSO- 
lithium acetate method [15] and plated on glucose-containing SD 
medium (2% glucose, 0.67% yeast nitrogen base, 0.1% casamino 
acids). The resultant colonies were transferred either with a nitrocel- 
lulose membrane to galactose-containing plates (2% galactose, 0.67% 
yeast nitrogen base, 0.1% casamino acids) for clone selection, or to 
galactose-containing liquid medium for measurement of cell growth 
parameters. 
DNA from yeast cells was isolated by the method described in [16] 
and used for transformation of bacterial cells for subsequent dideoxy 
sequencing and rearrangement of plasmid inserts. 
The procedure for ProTcL isolation from yeast cells was as described 
[ill. 
3. Results _ 
In order to identify functionally important amino acid res- 
idues in human ProTa, random mutagenesis of ProTa 
cDNA was performed via error-prone PCR on the pHTl5 
with direct and reverse primers. pHTl5 is a derivative of 
pUCl9, in the SmaI site of which a full-length protein-coding 
region of the human ProTa cDNA was inserted [13]. Mutated 
PCR products of approx. 430 bp long were purified, digested 
with BamHI and EcoRI, and cloned into the pYeDPl/S-2 
shuttle vector under the control of GALlO-CYCl promoter, 
which could be induced by growing yeast cells in the galac- 
tose-containing medium (Fig. 1). 
For selection of ProTa mutants with altered properties of 
the protein, use was made of the fact that wild-type human 
ProTa, being overproduced in S. cerevisiue cells, efficiently 
blocks yeast cell growth [ll]. Thus, plating the yeast cells 
bearing pYeDPlB-2 derivative containing wild-type human 
ProTa cDNA resulted in colony formation when transcrip- 
tion of the human gene was blocked (i.e. no galactose was 
present in the medium), but failed to produce colonies when 
ProTa synthesis was induced by the addition of galactose. In 
the present approach, yeast cells were transformed with a 
mixture of plasmids bearing mutated ProTa cDNAs, plated 
on the galactose-free medium, and the resultant colonies were 
replica-plated on the galactose-containing medium in order to 
induce production of human ProTa. A number of yeast 
clones which gained the ability to grow in the presence of 
synthesized mutant ProTa were thus selected, and one of 
them was subjected to detailed analysis. 
Plasmid DNA was recovered from this clone and re-trans- 
formed into E. coli cells, with subsequent sequence determina- 
tion of the mutated ProTa cDNA. Nine nucleotide differences 
leading to three amino acid substitutions were identified: S’T, 
NsgD and Ks7E. To evaluate contribution of a single muta- 
tion in the obtained growth phenotype, ProTa cDNA inser- 
tion was reconstituted by replacement of mutated AcyI-EcoRI 
DNA fragment with the wild-type ProTa cDNA AcyI-EcoRI 
fragment leading to production of ProTa with the single S’T 
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Fig. 1. Schematic representation of the approach aimed at identification of functionally important amino acid residues in human ProTo. 
mutation; and by replacement of mutated BumHI-DdeI 
cDNA fragment with the appropriate wild-type DNA frag- 
ment leading to production of ProTa with the single Ks7E 
mutation (Fig. 1). 
Production of both S’T and Ks7E ProTo mutants in yeast 
cells bearing appropriate plasmids was demonstrated by iso- 
lation of respective proteins from the cells grown in glucose- 
containing medium and then shifted to galactose-containing 
medium for 8 h to induce ProTa synthesis (Fig. 2A, lanes l- 
3). 
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was Fig. 2. (A) Synthesis of wild-type human ProTa (lanes 1,4), S’T mutant (lanes 29 and K*‘E mutant (lanes 3,6) in yeast. Human ProTa 
isolated from yeast cells induced with galactose for 8 h (lanes l-3) or for 72 h (lanes 46). The amount of cells taken for ProTa isolation in 
samples 4-6 was several times higher than that in samples 1-3 in order to visualise the low amount of wild-type ProTo: and S’T mutant if 
present. The preparations were analysed by 8% polyacrylamide/urea gel electrophoresis followed by methylene blue staining [ll]. The positions 
of ProTa and tRNA are indicated. (B) Growth of yeast cells producing: 1, wild-type human ProTa; 2, S’T mutant; 3, Ks7E mutant; 4, no 
ProTa (vector alone). 
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Fig. 3. Alignment of the carboxy-terminal sequence of human 
ProTa with the bipartite NLS of nucleoplasmin. Basic residues es- 
sential for nucleoplasmin NLS functioning and corresponding 
ProTa residues are in bold. The mutation in ProTa sequence lead- 
ing to inactivation of the protein is indicated by the arrow. 
identification of the functionally important amino acid resi- 
dues in ProTa. In this case, a strategy for selection of such 
mutants appeared to be straightforward: only those mutations 
which inactivate ProTa will gain the ability of ProTa-produc- 
ing yeast colonies to form, while the growth capability of all 
other colonies producing mutated but still active ProTa will 
still be retarded. Then sequencing of cDNA encoding inacti- 
vated ProTa should point to the amino acid residues which 
are important for ProTo functioning. 
As a first example of utilisation of this approach, we have 
identified Lys-87 of human ProTo as a functionally important 
amino acid residue. Conversion of Lys-87 to glutamic acid 
resulted in abrogation of the inhibitory properties of human 
ProTa on yeast cell growth. Interestingly, because several 
mutations were simultaneously introduced in one cDNA mol- 
ecule, it became possible, after recloning, to identify not only 
the important Lys-87, but also the Ser-1 which appeared to be 
dispensable for ProTo functioning, at least in the assay em- 
ployed. 
The main question concerning inactivating mutation Ks7E 
is whether any biological significance could be inferred from 
these data. Inactivation of ProTo by this particular mutation 
is formally similar to abrogation of inhibitory action of 
ProTo on yeast cell growth resulted from elimination of the 
last nine carboxy-terminal amino acid residues of ProTa in- 
cluding putative NLS [l 11. Although this analogy might well 
be accidental, it prompted us to take a closer look at the 
carboxy-terminal sequence of ProTa. The region of the 
ProTo molecule in question is believed to contain a NLS of 
this nuclear protein. Although this NLS has never been pre- 
cisely identified, several lines of evidence suggest that a basic 
sequence KKQK (residues 101-104) may contribute to the 
active nuclear import of this protein, in analogy with the 
canonical continuous basic NLS of SV40 T antigen [3-5,171. 
There is yet another type of NLS in nuclear proteins exem- 
plified by the NLS of nucleoplasmin. This NLS is bipartite 
and is composed of two basic regions separated by a 10 amino 
acid long spacer (Fig. 3) [18,19]. Both parts of this NLS are 
essential for the nuclear uptake of the protein. The spacer 
length and composition can be altered without significant af- 
fecting nuclear targeting; however, bulky hydrophobic amino 
acids should be avoided from this region [l&19]. 
Inspection of the carboxy-terminal portion of ProTa has 
revealed that a short basic region KR (residues 87-88) is lo- 
cated 12 amino acid residues upstream from the putative NLS 
(residues 101-104) (Fig. 3). The spacer region lacks bulky 
hydrophobic residues and thus conforms to the above-men- 
tioned rules for the bipartite NLS. It is most notable that the 
identified ProTa-inactivating mutation K*‘E destroys one 
part of this putative bipartite NLS. 
Thus, it is tempting to suggest that the NLS of ProTo 
might actually be bipartite rather than monopartite, and 
that the inability of Ks7E ProTa mutant to suppress yeast 
cell growth is due to relaxation of its NLS which prevents 
efficient nuclear uptake of the protein. This possibility is cur- 
rently under consideration. 
In order to determine which of these mutations may con- 
tribute to the inactivation of ProTa, growth parameters of the 
yeast cells bearing plasmids encoding wild-type ProTo, S’T 
and K*‘E mutants and vector alone were determined in the 
liquid medium. While in the absence of inducer (no ProTa 
production) all four types of cells grew equally well (not 
shown), synthesis of wild-type ProTa and SIT mutant in the 
presence of galactose led to severe inhibition of cell growth 
(Fig. 2B). In contrast, production of the Ks7E ProTo mutant 
exhibited no appreciable effect on yeast cell growth, which 
was comparable to the growth of the cells containing vector 
only. It should be mentioned that restoration of yeast cell 
growth observed at late stages (approx. 70 h post induction 
(Fig. 2B, curves 1,2) was demonstrated to be due to abroga- 
tion of wild-type and ‘SIT ProTo production by an unknown 
mechanism. Synthesis of KR7E ProTo mutant was still very 
efficient at this time point (Fig. 2A, lanes 46). This observa- 
tion further strengthens the notion that production of wild- 
type and SIT ProTo is deleterious for yeast cells, while Ks7E 
mutant lacks this property. 
Thus, our results clearly demonstrate that the single K87E 
mutation inactivates inhibitory action of human ProTa on 
yeast cell growth, while the S’T mutant preserves the proper- 
ties of wild-type protein. 
4. Discussion 
Generation of ProTa mutants with altered properties of 
this small nuclear protein appears to be an essential step in 
deciphering a function of ProTa and structure-function rela- 
tionship in this protein. Two major questions arise in this 
regard: which amino acid residues should be mutated, and 
what assay can be employed for identification of ProTo mu- 
tants with biologically significant amino acid substitutions? 
As for the first question, random mutagenesis of ProTa seems 
to be preferential, since no fruitful prediction of potential 
‘active sites’ in the protein could be made on the basis of 
analysis of its primary structure. To this end, we performed 
PCR-mediated random mutagenesis of the human ProTo 
cDNA based on the ability of Taq polymerase to misincorpo- 
rate nucleotides at rather high frequency, which could be 
further increased by the addition of manganese ions (see Sec- 
tion 2) [12]. 
In order to select ProTa mutants with altered properties of 
the protein, we made use of the fact that S. cerevisiae cells 
overproducing recombinant human ProTcx fail to grow [l 11. 
We have demonstrated recently that deletion of the last nine 
carboxy-terminal amino acids of ProTo containing putative 
NLS abolished inhibitory action of the protein [l 11. It seemed 
probable, therefore, that some point mutations could abrogate 
inhibitory properties of the protein as well, thus permitting 
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